CAMBRIDGE, Mass. — March 3, 2026 — Leads & Copy — Vericel Corporation (NASDAQ:VCEL) will present at two upcoming investor conferences.
The advanced therapies company, which focuses on the sports medicine and severe burn care markets, will present at the TD Cowen 46th Annual Healthcare Conference on Wednesday, March 4th, 2026, and the Leerink Partners 2026 Global Healthcare Conference on Tuesday, March 10th, 2026.
Webcasts of the presentations will be available in the Investor Relations section of Vericel Corporation’s website.
Vericel markets three products in the United States: MACI® (autologous cultured chondrocytes on porcine collagen membrane), Epicel® (cultured epidermal autografts), and NexoBrid® (anacaulase-bcdb).
MACI® is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel also holds an exclusive license for North American rights to NexoBrid®, a biological orphan product containing proteolytic enzymes, which is indicated for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns.
Epicel® and MACI® and MACI Arthro® are registered trademarks of Vericel Corporation. NexoBrid® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. ©2026 Vericel Corporation. All rights reserved.
Source: Vericel Corporation
